BOSTON–(Business Wire)– Genetics of 1910 (or “1910”)is the only biotech company to advance small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, and today announced that it will leverage advanced artificial intelligence (AI) and the following technologies: announced a new five-year commercial agreement and go-to-market collaboration with Microsoft. -A generation of high performance computing (HPC) could reverse 70 years of productivity decline in pharmaceutical R&D.
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20240229216281/en/
A 1910s state-of-the-art laboratory automation facility located in Boston’s Seaport District. (Photo: Business Wire)
1910 combines its vast computational and wet lab biological data, robotics-driven lab automation, and multimodal AI models for drug discovery with Microsoft’s HPC platform, Azure Quantum Elements, at the intersection of AI and research. Empowering researchers around the world with a groundbreaking, purpose-built cloud platform. HPC accelerates scientific discovery.
1910 provides a platform for pharmaceutical, biotech, government, academic, and research institutions through three partnership models: co-discovery, co-engineering, and platform-as-a-service. Potential partners can sign up here to get early access.
“We are excited to work with 1910 Genetics to bring their pioneering AI drug discovery engine to Azure Quantum Elements.” “We’re thrilled to be partnering with Microsoft,” said Jason Zander, executive vice president of strategic mission and technology at Microsoft. “This breakthrough technology holds tremendous promise for accelerating the design of small and large molecule therapeutics. Our collaboration with 1910 Genetics is a testament to our shared commitment to innovation and drug discovery. We look forward to seeing what pharmaceutical researchers can achieve with our shared efforts. .”
AI enables a paradigm shift in scientific discovery
Since 17 yearsth Centuries later, the scientific method has remained largely unchanged, relying on slow, intensive, human-driven, iterative cycles of observation, hypothesis, experiment, and analysis. AI offers an unprecedented opportunity to compress these cycles, shorten the time between observation and discovery, and reduce the need for experimentation.
This paradigm shift in AI for scientific discovery will transform discovery across all industries, especially the pharmaceutical industry, where new drug development takes an average of 12 to 15 years and costs more than $2 billion. Realizing the promise of AI for scientific discovery in pharmaceutical R&D will require rethinking new end-to-end drug discovery and development processes from the ground up using AI, replacing historically fragmented We need to overcome heterogeneous data and create new types of data. Put massively parallel data, AI, and lab automation into the same iterative loop.
1910 Genetics is realizing the potential of AI to accelerate R&D productivity
Founded in 2018 and backed by major investors including OpenAI’s Sam Altman, M12-Microsoft’s Venture Fund, and Playground Global, 1910 is a next-generation AI company with three differentiating capabilities: Built from the ground up as a native biotech company.
- To overcome the data scarcity problem in the pharmaceutical industry, 1910 generates three unique data streams at scale. Computational data using atomistic modeling and simulation, wet lab proxy biological data using next generation sequencing, and wet lab ground truth biological data spanning biochemical, cellular, and biological data. in vivo Assay.
- A 1910s state-of-the-art laboratory leverages robotics and automation to create large-scale wet lab proxies and ground truth biological data for AI training and molecular testing of synthetic drug candidates. of parallel data, AI, and automation into the system. Same repeat loop.
- For modality-independent drug discovery, the 1910 multimodal AI platform can design large molecule therapeutics as well as traditional small molecules, which make up 90% of drugs approved today.
For pharmaceutical R&D teams, the 1910 platform provides novel leads for a variety of therapeutic targets across target classes ranging from proteases, kinases, and transmembrane receptors, and disease areas ranging from neuroscience, infectious diseases, and autoimmunity. Significantly reduce the time and cost of designing molecules. diseases, cancer, etc.
Microsoft Azure Quantum Elements is purpose-built to accelerate scientific discovery
“Azure Quantum Elements brings the most powerful AI engine created to power this new wave of AI for scientific discovery,” he said. said Zulfi Alam, Corporate Vice President, Microsoft Quantum. “With 1910, Microsoft is charting a path to a billion-dollar business in AI-driven drug discovery and development.”
In June 2023, Microsoft introduced Azure Quantum Elements (AQE), a chemistry supercomputer containing AI models trained on hundreds of millions of molecules. This makes Microsoft an expert in chemistry and materials science and a “co-pilot for Azure” using generative AI. Quantum” to write code and answer tough questions for computational chemists and materials scientists.
On January 9, 2024, just six months after its launch, Microsoft announced the first concrete case study of Azure Quantum Elements for Chemistry, demonstrating how Azure Quantum Elements uses advanced AI to screened 32.6 million candidates and demonstrated the discovery and synthesis of new materials. The use of lithium in batteries could be reduced by 70%, paving the way for the next generation of sustainable batteries. This groundbreaking discovery is the first to apply AI for scientific discovery to the design of new materials and demonstrates the transformative potential of Azure Quantum Elements to improve productivity in more industries, including pharmaceuticals. I have a feeling that
1910 Genetics and Azure Quantum Elements are building the infrastructure layer
“We are excited to begin this collaboration with Microsoft and integrate our large and small drug discovery platforms into Azure Quantum Elements.” Founder and CEO Dr. Jen Nwankwo said: “By building an infrastructure layer for AI-driven drug discovery, we will extend the reach and impact of our platform to researchers around the world.”
1910’s relationship with Microsoft began in 2021 when M12-Microsoft’s venture fund led a $22 million Series A investment in 1910 Genetics. In June 2023, Microsoft announced that 1910 is one of his six launch customers for Azure Quantum Elements and the only collaborator in the biotech and pharmaceutical industries.
With today’s announcement, 1910 and Microsoft are expanding their pilot partnership into a five-year commercial agreement and go-to-market partnership to leverage biotech companies’ vast computational and wet-lab biological data, robotics-driven lab automation, and We will have a go-to-market partnership combining modal AI models. Drug discovery using Azure Quantum Elements.
Together, the companies will help pharmaceutical and R&D teams around the world begin and accelerate the transition to AI-driven drug discovery today, and improve tomorrow’s drug discovery, commercialization, post-market surveillance, and real-world evidence-based approaches. Build the infrastructure layer to initiate, accelerate, and enable migration.
Added Jen Nwankwo, Founder and CEO of 1910. “As the biopharmaceutical industry prepares for the inevitable transition from human-intensive, rational drug discovery to AI-enabled drug discovery powered by frontier-generated AI, the companies that will win will be We believe we will be the company that innovates across drug discovery, just like it did in 1910.” A technology stack for performance computing today and quantum computing tomorrow. By integrating 1910 with Azure Quantum Elements, biopharmaceutical companies around the world can realize the potential of AI and reverse decades of R&D productivity decline. ”
Potential customers interested in learning more about 1910 Genetics’ small and large molecule drug discovery platform on Azure Quantum Elements can sign up here for early access.
1910 About genetics
1910 Genetics is the only biotechnology company using a multimodal AI platform powered by laboratory automation to advance small and large molecule drug discovery. We integrate AI with three proprietary data streams (computational data, wet lab proxy biological data, and wet lab ground truth biological data) to deliver new drug candidates and software solutions to leading pharmaceutical companies and technologies. to our partners and advance our internal pipeline in neurological and autoimmune diseases. diseases, cancer, etc. 1910 was founded in 2021 with $26.1 million in seed and Series A funding, backed by M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, FoundersX Ventures, and other leading investors. I did. Since then, the company has established a headquarters and research facility in Boston’s Seaport District and continues to employ a world-class team. For more information, visit 1910Genetics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229216281/en/
A 1910s state-of-the-art laboratory automation facility located in Boston’s Seaport District. (Photo: Business Wire)
